Comparative evaluation of efficacy of single pre-emptive dose of Extended release Lornoxicam versus Prolonged release Diclofenac for surgical removal of impacted 3rd molar in Indian population: A prospective, randomized, triple blind, split mouth clinical trial. - NI

Terna Dental College0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年4月29日

试验速览

暂无简介。

•1. Patients who are willing to participate in the study
•2.Patients requiring surgical extraction of bilateral impacted mandibular 3rd molar of similar difficulty (easy or moderate difficulty as per Pederson’s difficulty index)
•3.Healthy patients belonging to ASA Class I or II will be included
•4.Patients who are not on any pain management therapy or those who have not consumed any NSAID in the last seven days.

•1.Patients not willing to participate in the study
•2.H/o Hypersensitivity reactions to Lornoxicam, Diclofenac or any other NSAID
•3.Pregnant and lactating patients
•4.Patients suffering from Bronchial Asthma or COPD or bleeding diathesis.
•5.Patients with H/o gastritis, gastric/ duodenal ulcers, or any other inflammatory gastrointestinal disease
•6.Pederson difficulty index score 7-10 (Difficult)
•7.Patients having local signs of infection around the impacted tooth to be removed such as periapical abscess/granuloma, pericoronal abscess, fascial space infection etc.

发起方